Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs

Douglas Barker1, Karen T. Gillum2, Nancy A. Niemuth2, Shantha Kodihalli1*

1 Research and Development, Emergent BioSolutions Canada Inc., Winnipeg, Manitoba, Canada, 2 Battelle Biomedical Research Center, West Jefferson, Columbus, Ohio, United States of America

Abstract

Botulinum neurotoxins are highly toxic and are potential agents for bioterrorism. The development of effective therapy is essential to counter the possible use of these toxins in military and bioterrorism scenarios, and to provide treatment in cases of natural intoxication. Guinea pigs were intoxicated with a lethal dose of botulinum neurotoxin serotypes A, B, C, D, E, F or G, and at onset of the clinical disease intoxicated animals were treated with either BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)–(Equine)] or placebo. BAT product treatment significantly (p<0.0001) enhanced survival compared to placebo for all botulinum neurotoxin serotypes and arrested or mitigated the progression of clinical signs of botulism intoxication. These results demonstrated the therapeutic efficacy of BAT product in guinea pigs and provided supporting evidence of effectiveness for licensure of BAT product under FDA 21 CFR Part 601 (Subpart H Animal Rule) as a therapeutic for botulism intoxication to serotypes A, B, C, D, E, F or G in adults and pediatric patients.

Introduction

Botulinum neurotoxins (BoNTs) are considered to be some of the most toxic substances known, with an estimated human lethal dose fifty (HLD₅₀) of 1 ng/kg body weight [1]. Produced from spore-forming Gram-positive bacteria belonging to the genus Clostridium, BoNTs cause paralysis by blocking the release of acetylcholine at peripheral cholinergic nerve terminals of the skeletal and autonomic nervous systems [2]. BoNTs have been classified as category A biothreat agents in the United States [3]. The rationale behind this designation is the extreme potency of the toxin, the relative ease with which it can be isolated and used with malice and the severity of the clinical disease caused by the toxin [4].

In the United States, a total of 182 confirmed and 13 probable cases of botulism were reported to the Centers for Disease Control and Prevention (CDC) in 2017 [5]. In Europe, 201 suspected and 146 confirmed cases were reported in 2015 by a total of 18 European Union/European Economic Area (EU/EEA) countries with a notification rate of <0.1 cases per
100,000 population. Human botulism mortality rates have been reported as high as 60% [6,7]; however, with improved supportive care including respiratory support and antitoxins, mortality rates have decreased significantly in recent years [5,8]. The duration of hospitalization and length of stay in the intensive care unit (ICU) continues to present a significant burden to the healthcare system.

Humans are susceptible to all seven serotypes; thus, any one of them could be used for bioterrorism [9–20]. However only certain serotypes are associated with human botulism, including BoNT serotypes A, B, E and F. There are currently no FDA approved vaccines available for prevention of botulism in humans against any of the seven serotypes, and until the licensure of BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)–(Equine)] in the United States, no therapeutic was available to treat intoxication by all seven BoNT serotypes. The approval of equine botulism antitoxin in the past was based on clinical experience; however, the botulism incidence is too low to conduct carefully controlled clinical trials. Therefore, BAT product was developed for licensure in the United States under 21 CFR Part 601 (Subpart H, Animal Rule), ‘Approval of Biological Products When Human Efficacy Studies Are Not Ethical or Feasible.’ Under this rule, approval is based on adequate and well-controlled animal efficacy studies in two animal models, to establish that the drug is reasonably likely to produce clinical benefit in humans, in addition to establishing safety in humans.

Furthermore, a clearly defined trigger for initiation of treatment is required for use in animal efficacy studies for the treatment indication. BAT product was licensed by the United States Food and Drug Administration on 22 March 2013. It is currently the only botulism antitoxin licensed for the treatment of symptomatic botulism following documented or suspected exposure to any of the known seven BoNT serotypes in adults and pediatric patients.

BAT product is a sterile solution of F(ab’)2 and F(ab’)2-related antibody fragments prepared by blending plasma obtained from horses immunized with a specific BoNT serotype (A, B, C, D, E, F or G) of botulinum toxoid and toxin into a final heptavalent product. The guinea pig was selected as a relevant model for efficacy evaluation because of its susceptibility to all seven BoNTs [21]. In addition, there is a large body of data demonstrating the reproducibility and usefulness of guinea pigs for the efficacy evaluation of botulism vaccines and antitoxins [21–24]. Although the subtle signs of botulism such as ptosis are not visible in guinea pigs, intoxication results in muscular weakness, respiratory distress, paralysis and death mimicking the human clinical scenario [21]; thus, the response in these animals is predictive of the response in humans, an important consideration for product evaluation.

The therapeutic efficacy of BAT product in comparison to a placebo (46.6% vs.0%) against BoNT serotype A in rhesus macaques has been reported previously [25]. The post-exposure prophylactic efficacy of BAT product in comparison to the placebo against all seven serotypes (>95% survival vs.0% for each serotype) in guinea pigs has also been established [21]. The therapeutic efficacy of BAT product (i.e. when given after confirmed signs of intoxication) against any of the seven BoNT serotypes mimicking the clinical use of BAT product had not been demonstrated.

For the evaluation of therapeutic efficacy, the BAT product was administered to symptomatic guinea pigs to mimic the product use in a clinical setting. The results of these pivotal studies along with the demonstrated effectiveness of BAT product in rhesus macaques [25] provided evidence of effectiveness for successful licensure.

Materials and methods

Experimental plan

Three separate studies were conducted.
Study 1 was conducted to evaluate the efficacy of BAT product in rescuing animals intoxicated with 4x GPIMLD₅₀ (guinea pig intramuscular lethal dose 50) of BoNT serotypes A, C, D or F. This study was conducted in two phases; Phase 1 examined BoNT serotypes A and F, and Phase 2 examined BoNT serotypes C and D. Between thirty-one to thirty-five Hartley Guinea Pigs approximately gender-balanced were randomly assigned to either BAT product or placebo-control treatment groups for each BoNT serotype.

Study 2 was conducted to determine an intoxication dose for each of BoNT serotypes A, B, C, D, E, F and G that would be highly lethal while providing an adequate window to allow for the rescue of animals in a pivotal efficacy study. Seventy Hartley Guinea Pigs were randomized into seven groups of 10 animals each. Groups were gender balanced. Six groups received a single intramuscular injection of either BoNT serotype A or BoNT serotype E toxin at a dose equivalent to 4.0x, 2.0x or 1.5x GPIMLD₅₀. A seventh group received saline only and acted as concurrent controls.

Study 3 was the pivotal 21-day survival study to demonstrate the efficacy of BAT product in rescuing animals intoxicated with BoNT serotypes A, B, C, D, E, F or G. Four hundred and seventy-six Hartley Guinea Pigs were randomized into fourteen groups of 34 animals each. Groups were gender-balanced. Animals were assigned to either BAT product or placebo-control treatment groups for each BoNT serotype. Due to a large number of animals used in this study, the study was conducted in seven separate phases, one for each BoNT serotype.

Animals, husbandry and veterinary care
All experiments were conducted with Hartley guinea pigs (*Cavia porcellus*) supplied by Charles River Laboratories (Kingston, NY and Raleigh, NC locations). Each animal was received from the supplier with a surgically implanted jugular vein catheter. Animals that were in good health, free of malformations, and exhibiting no signs of clinical disease were released from quarantine by the BBRC facility veterinarian. Animal husbandry was in accordance with the standards specified in the "Guide for the Care and Use of Laboratory Animals" [26].

Animals were individually housed in polycarbonate cages in stainless steel racks, equipped with automated watering systems maintained on 24-hour continuous room lighting to allow for clinical observations. The bedding material utilized was Sani-chips® hardwood heat-treated chips. Animals received both water and PMI Certified Guinea Pig Diet 5026 ad libitum. Housing room temperatures were maintained at 68 to 75˚F, and relative humidities were 32 to 70% while study animals were present. To reduce stress on the animals and to provide optional shelter from continuous room lighting, each animal was provided with a tinted individual plexiglass “hut” within the cage. The huts were removed from cages after observation of the first severe clinical sign or if the shelter interfered with the animal’s mobility. Animals were identified by individual cage cards and ear tags.

Guinea pigs were randomized pre-study intoxication on Day -1 to the treatment or control group.

The dose of neurotoxin administered was verified at BBRC using a mouse potency assay in male CD-1 (ICR) mice according to procedures described by Cardella [22].

Body weight
The specified pre-intoxication weight range for animals on all studies was 400.0 to 500.0 g. Botulinum neurotoxin serotype D animals on Study 3 weighed between 350.0 g and 525.0 g prior to intoxication since the majority of females available for this cohort were underweight. Body weights were measured at the following time points: Study Days -1, 7, 10, 14 and 21.
Botulinum neurotoxin intramuscular intoxication

Botulinum neurotoxin serotypes A, B, C, D, and E were produced at the University of Wisconsin; BoNT serotypes F and G were produced at Metabiologics, Inc. (Madison, Wisconsin). Potencies of all BoNT serotypes are given in S1 Table. Botulinum neurotoxin serotypes A, B, C, D, E, and F were received as ammonium sulfate precipitates and were reconstituted in phosphate-buffered saline (PBS). Botulinum neurotoxin serotype G was received in PBS, pH 6.2 (ammonium sulfate was removed by the manufacturer; therefore, no reconstitution was required). All BoNTs used in this study were in the complex form [27] consisting of the toxin and non-toxin-associated proteins. The LD$_{50}$ was established previously [21]. The toxin was administered as a single 0.1 mL intramuscular (IM) injection of a specific BoNT serotype (A to G at doses equivalent to 4x GPIMLD$_{50}$ to 1.5x GPIMLD$_{50}$, see S1 Table) into the muscles of the right hind leg. Toxin dose administered was verified by mouse potency assay.

Test and placebo control article intravenous administration

A preliminary study (Study 1) was conducted to evaluate the efficacy of BAT product against a limited number of toxin serotypes. For this study guinea pigs were intoxicated with BoNT toxins (A, C, D, or F) at 4.0x GPIMLD$_{50}$ via the IM route. Animals were treated IV with a single dose of placebo or a single scaled human dose of BAT product based on previous studies [21,25]. Briefly, assuming the average human weight of 70 kg and BAT product dose of 1 vial/person, the dose volume/kg of one scaled human dose equals to 1/70 of a vial or 0.16 mL/kg based on the 11.17 mL fill volume for the lot of BAT product used for these studies. This is consistent with FDA guidance, which states that for biologicals with molecular weight $>100$ kDa, the dose should be normalized on a mg/kg basis [28]. The toxin neutralization capacity administered based on the label claim for the lot of BAT product used for these studies is given in S2 Table. The product was administered immediately after the first observed moderate/severe clinical sign (treatment trigger) of intoxication.

For Study 2, no test or control article was administered.

For Study 3, guinea pigs were intoxicated with BoNT toxins (A, B, C, D, E, F, or G) at 1.5 x GPIMLD$_{50}$ via the IM route. The trigger for treatment with a single dose of placebo or a single scaled human dose of BAT product was defined as the fourth consecutive occurrence of a moderate or severe clinical sign of intoxication. Within 45 minutes of the trigger for treatment, each animal was intravenously administered with either test or control article. The treatment was administered via the indwelling venous catheter. Catheter patency was confirmed by visualization of blood in the catheter lumen immediately prior to treatment.

The test article was Botulism Antitoxin Heptavalent (serotypes A, B, C, D, E, F, and G)–(equine), Lot 2060401Y, manufactured by Emergent BioSolutions Canada Inc. (Winnipeg, Manitoba Canada). It is a sterile solution which should be stored at -15 to -25˚C. The manufacturing process, label claims for potency and toxin neutralization capacity for this product are described in detail by Emanuel and Kodihalli [21,25]. The same lot of BAT product was used for both Study 1 and Study 3. Toxin potency for each serotype ranged from 1,229 U/vial (BoNT serotype G) to 10,690 U/vial (BoNT serotype E, see S2 Table).

The control article was Botulism Antitoxin–Placebo, Lot #10703480 from Emergent BioSolutions Canada Inc. (Winnipeg, Manitoba, Canada). Botulism Antitoxin Placebo (normal equine immune globulin) was manufactured using a procedure similar to the manufacture of BAT product described elsewhere [21]. Placebo had a protein concentration of 50 mg/mL and potency of < 0.38 Units/vial against all seven BoNT. This material is described as a clear to opalescent liquid essentially free of foreign particles in a 20 cc Type 1 glass container. The same lot of Botulism Antitoxin Placebo was used for both Study 1 and Study 3.
The test and control article dilution material was normal saline (0.9% sodium chloride USP lot #J8H009) manufactured by Baxter. It was stored at controlled room temperature per manufacturer’s specifications.

Euthanasia criteria

Any animals meeting a criterion for euthanasia were pre-terminally euthanized. The three criteria were: (1) any animal having a 25% or greater weight loss (when compared to last pre-intoxication body weight) in conjunction with any concurrent severe sign of intoxication; (2) any animal that has two consecutive observations of total paralysis; and (3) any animal that did not meet either of the first two criteria but was judged to be moribund. Only the Study Director (or the Battelle staff veterinarian in consultation with a lead technician if Study Director was not available) determined if an animal was moribund.

Animals that required euthanasia were first administered 0.3 mL xylazine hydrochloride (20 mg/mL) and 0.4 mL ketamine hydrochloride (100 mg/mL) by IM injection and then administered a lethal dose of Fatal-Plus (a euthanasia agent containing pentobarbital).

Clinical observations

Efficacy of BAT product in animals intoxicated with 4x GPIMLD50 of botulinum neurotoxin (study 1). Observations were initiated 12 hours post intoxication and performed hourly until every animal received treatment. Following treatment of the last animal, and continuing through Day 7, observations were made once every 3 hours and from Day 8 to 21 twice daily at least 6 hours apart.

Determination of botulism neurotoxin intoxication dose to demonstrate efficacy (study 2). Observations were made at 6 hours post-challenge for BoNT serotype E, and within 18 hours post-challenge for BoNT serotype A. Animals were observed frequently (hourly to once every 8 hours for BoNT serotype A, half-hourly to hourly for BoNT serotype E) until study termination (Day 14). Animals judged to be in poor and deteriorating condition were euthanized.

Pivotal therapeutic efficacy of BAT product in guinea pigs intoxicated with 1.5x GPIMLD50 of botulinum neurotoxin (study 3). A pilot study was conducted prior to the pivotal efficacy study with a toxin dose of 1.5x GPIMLD50 for a few of the serotypes in which animals reverted to being asymptomatic (data not shown) after the onset of moderate clinical signs including right hind limb weakness (treatment trigger). To avoid treating animals with transient clinical signs, an objective, unambiguous and reliable trigger for treatment consistent across all serotypes was determined to be observation of four consecutive signs of any moderate (salivation, lacrimation, weak limbs, right hind limb weakness, changes in breathing sounds or patterns) or severe signs (forced abdominal respirations, total paralysis), although not necessarily four consecutive observations of the same sign of intoxication, by trained personnel. To ensure that the clinical sign assessment was objective and reproducible, the personnel conducting clinical observations were required to pass a proficiency test prior to study start confirming their ability to identify symptoms in guinea pigs after intoxication.

Observations were initiated within 6 hours post-intoxication for BoNT serotypes C, E and F; and within 12 hours post-intoxication for BoNT serotypes A, B, D and G. Guinea pigs were monitored for signs of intoxication either hourly ± 15 minutes (BoNT serotypes A, B, C, D and G) or every half hour ± 15 minutes (BoNT serotypes E and F). As soon as each animal showed its fourth consecutive moderate/severe clinical sign (i.e. trigger) of botulism, it was treated within 45 minutes with either BAT product or placebo-control (as appropriate).
Animals were treated upon four consecutive observations of moderate or severe signs of botulinum intoxication to provide confidence that animals are showing the actual onset of clinical disease. The majority of animals were treated based on observation of right hind limb weakness (defined as the animal failing to exhibit a clutch response to a blunt object inserted across the rear leg claws) or change in breathing sounds or pattern (defined as change in breathing with audible sounds, excessive deep or shallow or irregular breathing).

Each animal was intravenously administered with BAT product or placebo control (1.0 mL per 500 g body weight) article via an indwelling venous catheter adjusted to the correct volume immediately prior to administration. Time of administration was recorded immediately post-dose. Following treatment of the final animal in each serotype, observations were reduced to every 3 hours until study Day 10, or later if there were no clinical signs, they were reduced to once every 6 hours and from Day 15 to twice daily (at least 6 hours apart) until study termination on Day 21.

**Data analysis**

Statistical analyses were performed using Stata (version 11.1). Survival was the primary endpoint, secondary endpoints including the incidence of clinical signs, time to death and clinical severity scores were analyzed. These secondary endpoints provide additional evidence of the efficacy of BAT product.

As Study 3 was the pivotal study for licensure under the Animal Rule (21 CFR 601.90) [29], analyses were conducted in a manner similar to that done for clinical trials. Specifically, an intent-to-treat (ITT) analysis set for each serotype was used, consisting of only those animals that were intoxicated with botulinum neurotoxin and survived to receive the test or placebo control article as appropriate for the treatment group to which they were assigned. Two animals (one intoxicated with BoNT serotype C and one intoxicated with BoNT serotype D) which died whose preceding clinical course was not consistent with BoNT intoxication and progression were retained for the analysis as the cause of death could not be determined based on pathology in these animals.

For each treatment and placebo group, the survival rate at 14- or 21-days post-intoxication was calculated, along with an exact 95% confidence interval for the survival rate using the Clopper-Pearson method.

Two-tailed Fisher’s exact tests were used to determine if there was a statistically significant difference between survival rates for the BAT product treatment group and the placebo control group or each serotype. Kaplan-Meier curves along with log-rank tests were used to compare the time to death between the BAT product treatment group and the placebo control groups for each serotype. The median time to death was determined along with a two-sided 95% confidence interval for each group using the product-limit method.

The incidence of clinical signs was calculated, along with an exact 95% confidence interval, using the Clopper-Pearson method. Two-tailed Fisher’s exact tests were then used to compare the incidence of clinical signs between the BAT product treatment group and the placebo control groups for each serotype. Kaplan-Meier curves along with log-rank tests were used to compare the time to onset of clinical signs between the BAT product treatment group and the placebo control group for each serotype. The median time to onset of clinical signs was determined along with a two-sided 95% confidence interval for each group using the product-limit method. This analysis was performed for each clinical sign, and the grouped clinical signs, by serotype.

The assessment of clinical severity was calculated for each animal in the analysis set, wherein mild clinical signs (lethargy) were assigned a value of “1”, moderate signs (salivation,
lacrimation, right hind limb weakness, weak limbs, change in breathing sounds or patterns) were assigned a value of “2”, severe signs (forced abdominal respirations, total paralysis) a value of “3”. For those animals which succumbed or were euthanized, a score of “20” was assigned for that time point and for all subsequent time points to end of the study. At each clinical observation time point, the clinical severity scores were calculated (cumulative for all the clinical signs observed at that time point for each animal) and averaged for each treatment group. For animals that survived to study end, the final sacrifice record was not used in the analysis.

Ethics statement

The research was conducted in compliance with the Animal Welfare Act (AWA, 7 U.S.C. §2131, 2002, 2007 and 2008) and other federal statutes and regulations relating to animals and experiments involving animals and adhered to the principles stated in the Guide for the Care and Use of Laboratory Animals [26]. All animal procedures were conducted under protocols (843-G005630 964-G005630 1180-G005630) approved by the Institutional Animal Care and Use Committees (IACUC) of Battelle Biomedical Research Center (BBRC), in accordance with IACUC guidelines, https://www.nal.usda.gov/awic/institutional-animal-care-and-use-committees.

Results

Efficacy of BAT product in guinea pigs intoxicated with 4x GPIMLD₅₀ of neurotoxin (study 1)

The in vivo therapeutic efficacy of BAT product was evaluated in groups of guinea pigs (n = 31 to 35/group) that were intoxicated intramuscularly (IM) with respective BoNT serotypes (A, C, D, F) at 4.0x guinea pig intramuscular lethal dose fifty (GPIMLD₅₀). Animals were treated intravenously (IV) with a single scaled human dose of BAT product or placebo immediately after the first observed moderate/severe clinical sign (treatment trigger) of intoxication. All placebo-treated animals died in all BoNT serotypes tested, confirming the lethality of the selected challenge dose. Five out of 35 guinea pigs treated with BAT product survived in BoNT serotype C group, and 2/31 survived in BoNT serotype F group (Table 1). There were no survivors in BoNT serotypes A (0/33) or BoNT serotype D groups (0/33). Survival observed with BAT product treatment compared to placebo was very low (0% - 14%); consequently, survival was not statistically different between the treatment and placebo groups for any of the four BoNT serotypes tested. All animals that died had clinical observations consistent with BoNT intoxication before death.

The mean and median times to death are given in Table 2. Median survival time was significantly longer for BAT product-treated groups compared with the placebo groups (p < 0.0001, Log-Rank Test) for BoNT serotypes A, C and D (63 vs 56, 107 vs 66 and 74 vs 59 hours respectively). No difference was noted for BoNT serotype F, where the median time to death for both groups was 41 hours. The time to onset of moderate clinical signs (i.e. trigger for treatment

Table 1. Mortality by BoNT serotype and group of guinea pigs intoxicated with 4x GPIMLD₅₀ BoNT and treated with placebo or 1x scaled human dose of BAT product.

| Group          | Serotype A | Serotype C | Serotype D | Serotype F |
|----------------|------------|------------|------------|------------|
| 1.0x BAT Product | 33/33 (100) | 30/35 (86) | 31/31 (100) | 29/31 (94) |
| Placebo        | 33/33 (100) | 34/34 (100) | 32/32 (100) | 32/32 (100) |

https://doi.org/10.1371/journal.pone.0222670.t001
(initiation) was consistent between BAT product and placebo control groups for all BoNT serotypes; however, there was a delay in time to onset of severe clinical signs (immediately preceding death) in treatment groups for three (A, C, D) of the four BoNT serotypes tested (Table 2).

The clinical progression was very rapid at 4x GPIMLD\textsubscript{50} dose of botulinum toxin for all 4 BoNT serotypes tested. There was an overlap in the time to onset of moderate (treatment trigger) and severe signs (Table 2). The delay in treatment while waiting for the onset of signs together with rapid clinical course resulted in survival of only 0–14% of animals (depending on BoNT serotype), compared to 0% of survival in the placebo groups. The time between the onset of clinical signs (time of treatment) and death was rapid and insufficient for BAT product treatment to prevent mortality, despite the excess neutralization capacity available in the dose of BAT product administered [21] (S2 Table). Thus, the guinea pig model using an exposure dose of 4x GPIMLD\textsubscript{50} is not appropriate for evaluation of the therapeutic efficacy of BAT product due to rapid progression of clinical disease at higher toxin dose. Consequently, it was necessary to extend the duration of clinical signs (time between treatment and death) by selecting a lower and more appropriate toxin dose to provide a greater opportunity for demonstration of the therapeutic efficacy of BAT product in this model.

### Determination of botulism neurotoxin intoxication dose to demonstrate efficacy (study 2)

An extensive time course and lethality evaluation of a range of toxin doses (4x, 2x, and 1.5x GPIMLD\textsubscript{50}, n = 10) of BoNT serotypes A and E were conducted to establish the toxin dose that provided the longest clinical course while still resulting in mortality for use in the pivotal therapeutic efficacy study. The selected BoNT toxins represent typical (Serotype A) and fast-acting (Serotype E) toxins. All animals intoxicated with BoNT serotypes (A and E) died or were euthanized before study Day 7. The median times to onset of clinical signs at 2x and 4x GPIMLD\textsubscript{50} were comparable for both BoNT serotypes; however, time to onset was longer at 1.5x GPIMLD\textsubscript{50} for BoNT serotype A (Table 3).

The duration of clinical signs decreased as the challenge dose increased for both BoNT serotypes. The median time from clinical onset to death in the 1.5x GPIMLD\textsubscript{50} dose group was approximately 4.6x and 2.6x longer than that of the 4x GPIMLD\textsubscript{50} dose group for BoNT serotypes A and E, respectively. The time to death of animals intoxicated with high toxin dose (4x GPIMLD\textsubscript{50}) was approximately 3.2x and 1.6x faster than the animals exposed to low dose (1.5x GPIMLD\textsubscript{50}) for BoNT serotypes A and E, respectively (Table 4).

| Serotype | Test Group | Mean Time to Onset in Hours | Time to Death in Hours | Log-Rank Test Time to Death Comparison (P-value) |
|----------|------------|----------------------------|------------------------|-----------------------------------------------|
|          |            | Moderate Signs (Range)     | Severe Signs (Range)   | Mean (Range)                                 | Median (95% Confidence Interval)             |                                           |
| A        | 1.0x BAT product | 35 (30, 44)               | 64 (34, 113)           | 68 (42, 131)                                 | 63 (59, 64)                                 | <0.0001*                                   |
|          | Placebo    | 35 (29, 43)               | 49 (34, 62)            | 54 (40, 65)                                 | 56 (47, 59)                                 |                                           |
| C        | 1.0x BAT product | 34 (20, 45)               | 97 (56, 125)           | 105 (63, 131)                               | 107 (86, 131)                               | <0.0001*                                   |
|          | Placebo    | 35 (22, 48)               | 68 (49, 110)           | 73 (59, 112)                                 | 66 (66, 71)                                 |                                           |
| D        | 1.0x BAT product | 29 (22, 32)               | 85 (44, 110)           | 86 (38, 131)                                 | 74 (70, 95)                                 | <0.0001*                                   |
|          | Placebo    | 28 (21, 43)               | 63 (41, 73)            | 60 (47, 80)                                 | 59 (55, 62)                                 |                                           |
| F        | 1.0x BAT product | 30 (23, 42)               | 46 (24, 94)            | 42 (28, 61)                                 | 41 (37, 47)                                 | 0.8827                                     |
|          | Placebo    | 31 (23, 42)               | 56 (24, 121)           | 47 (25, 129)                                 | 41 (37, 47)                                 |                                           |

* Comparison significant at the 0.05 level of significance

https://doi.org/10.1371/journal.pone.0222670.t002
In general, animals challenged with BoNT serotype E had a shorter clinical course than those intoxicated with BoNT serotype A. A toxin dose of 1.5x GPIMLD\textsubscript{50} was selected as the revised toxin dose for use in therapeutic efficacy studies for all seven toxin serotypes. This dose was expected to produce a more prolonged clinical course and consequently would provide an opportunity to demonstrate the therapeutic effect of BAT product while still resulting in complete mortality of control animals. Moderate clinical signs, including right hind limb weakness, were identified and selected as early signs for use as a trigger for treatment initiation.

### Pivotal therapeutic efficacy of BAT product in guinea pigs intoxicated with 1.5x GPIMLD\textsubscript{50} of neurotoxin (study 3)

The pivotal study was a randomized, blinded, and controlled GLP study. A total of 616 guinea pigs were randomized to fourteen gender-balanced groups (n = 34) and were intoxicated with

| Clinical Sign                           | Kaplan-Meier Median (95% Confidence Interval) | Time to Onset of Clinical Signs (Hours) in Each Study Group |
|-----------------------------------------|---------------------------------------------|------------------------------------------------------------|
|                                        | Serotype A                                  | Serotype E                                                  |
|                                        | 1.5x GPIMLD\textsubscript{50} | 2x GPIMLD\textsubscript{50} | 4x GPIMLD\textsubscript{50} | 1.5x GPIMLD\textsubscript{50} | 2x GPIMLD\textsubscript{50} | 4x GPIMLD\textsubscript{50} | PBS |
| Lethargy\textsuperscript{1}            | 74 (71, 81)                                | 45 (45, 59)                                                | 31 (27, 42)                                                | 24 (21, 26)                                                | 22 (21, 28)                                                | (17, —) | — |
| Salivation\textsuperscript{2}          | 73 (67, 75)                                | 55 (52, 71)                                                | 39 (36, 49)                                                | 50 (29, 50)                                                | 33 (33, —)                                                | 24 (19, 24) | — |
| Lacrimation\textsuperscript{2}         | 109 (103, 127)                              | 74 (67, 89)                                                | 51 (46, —)                                                | 72 (—)                                                    | 51 (28, 51)                                                | 26 (21, 26) | — |
| Weakness of the Right Hind Limb Only\textsuperscript{2} | 41 (34, 46)                                | 27 (27, 31)                                                | 24 (21, 25)                                                | 15 (13, 17)                                                | 16 (13, 18)                                                | 13 (12, 13) | — |
| Weak Limbs\textsuperscript{2}          | 61 (52, 69)                                | 45 (40, 48)                                                | 32 (27, 37)                                                | 21 (20, 24)                                                | 20 (17, 24)                                                | 15 (14, 17) | — |
| Noticeable Change in Breathing Sound Rate or Pattern\textsuperscript{2} | 48 (36, 48)                                | 55 (33, 36)                                                | 29 (29, 32)                                                | 22 (21, 24)                                                | 19 (15, 21)                                                | 14 (13, 16) | — |
| Forced Abdominal Respirations\textsuperscript{3} | 153 (125, 165)                             | 74 (69, 87)                                                | 43 (41, 45)                                                | 30 (26, 39)                                                | 26 (24, 30)                                                | 19 (17, 20) | — |
| Total Paralysis\textsuperscript{3}     | 165 (165, —)                               | 78 (69, 97)                                                | 45 (45, 47)                                                | 32 (30, 41)                                                | 29 (26, 34)                                                | 21 (20, 22) | — |
| Any Moderate Sign                      | 37 (32, 42)                                | 27 (27, 31)                                                | 24 (21, 25)                                                | 14 (10, 17)                                                | 16 (12, 18)                                                | 13 (12, 13) | — |
| Any Severe Sign                        | 153 (125, 165)                             | 72 (69, 87)                                                | 43 (41, 45)                                                | 30 (26, 39)                                                | 26 (24, 30)                                                | 19 (17, 20) | — |
| First Clinical Sign                    | 37 (32, 42)                                | 27 (27, 31)                                                | 24 (21, 25)                                                | 14 (10, 17)                                                | 16 (12, 18)                                                | 13 (12, 13) | — |

— The clinical sign was not observed or the Kaplan-Meier estimates could not be calculated due to censoring

\textsuperscript{1} Mild signs of botulinum intoxication

\textsuperscript{2} Moderate signs of botulinum intoxication

\textsuperscript{3} Severe signs of botulinum intoxication

https://doi.org/10.1371/journal.pone.0222670.t003

### Treatment of botulism intoxication in guinea pigs

In general, animals challenged with BoNT serotype E had a shorter clinical course than those intoxicated with BoNT serotype A. A toxin dose of 1.5x GPIMLD\textsubscript{50} was selected as the revised toxin dose for use in therapeutic efficacy studies for all seven toxin serotypes. This dose was expected to produce a more prolonged clinical course and consequently would provide an opportunity to demonstrate the therapeutic effect of BAT product while still resulting in complete mortality of control animals. Moderate clinical signs, including right hind limb weakness, were identified and selected as early signs for use as a trigger for treatment initiation.

| Serotype | Group | Median Duration in Hours of Clinical Signs (Range) | Mean Time to Death in Hours (Range) | Median Time to Death in Hours (95% Confidence Interval) |
|----------|-------|---------------------------------------------------|------------------------------------|-----------------------------------------------------|
| A        | 1.5x GPIMLD\textsubscript{50} | 121 (72, 129)                                      | 143 (102, 165)                     | 165 (102, 165)                                      |
|          | 2x GPIMLD\textsubscript{50}   | 63 (52, 71)                                        | 92 (69, 143)                       | 92 (79, 99)                                        |
|          | 4x GPIMLD\textsubscript{50}   | 26 (25, 34)                                        | 52 (46, 66)                        | 51 (47, 57)                                        |
| E        | 1.5x GPIMLD\textsubscript{50} | 21 (12, 24)                                        | 39 (25, 95)                        | 32 (30, 39)                                        |
|          | 2x GPIMLD\textsubscript{50}   | 14 (11, 19)                                        | 31 (15, 57)                        | 30 (28, 32)                                        |
|          | 4x GPIMLD\textsubscript{50}   | 8 (7, 9)                                           | 21 (17, 28)                        | 20 (20, 22)                                        |
| Control  | —     | —                                                 | —                                  | —                                                  |

https://doi.org/10.1371/journal.pone.0222670.t004
a dose equivalent to 1.5x GPMILD$_{50}$ of the appropriate BoNT serotype (serotype A, B, C, D, E, F or G) given as a single intramuscular (IM) injection to the right hind limb. Due to the large sample size, the study was conducted independently for each BoNT serotype. At four consecutive occurrences of any moderate or severe signs, animals were treated IV with one human-scaled dose of BAT product.

There was a statistically significant (Fisher’s Exact Test, p<0.0001) enhancement in survival achieved with 1x scaled human dose of BAT product when compared to placebo for all BoNT serotypes (Table 5). Most treated animals, along with all placebo control animals, continued to progress from the trigger (right hind limb weakness in most cases) to develop systemic clinical signs such as a change in breathing and weak limbs. The treatment with BAT product resulted in virtually complete survival irrespective of the intoxicating BoNT serotype; however, mortality was lower than expected among BoNT serotype G placebo group. Even with the lower rate

| BoNT Serotype | Group | Treatment Dose Level | Median Time to Treatment (Min, Max)$^1$ in Hours | Survival (percent) | Two-Sided Fisher’s Exact Test Comparison (p-value) | Kaplan-Meier Median Time to Death (95% Confidence Interval in Hours) | Log-Rank Test Time-to-Death Comparison (p-value) |
|---------------|-------|---------------------|-----------------------------------------------|------------------|-----------------------------------------------|-------------------------------------------------|-----------------------------------------------|
| A             | A1    | 1.0x BAT Product    | 17 (15, 23)                                   | 34/34 (100%)     | <0.0001$^*$                                    | 99 (87, 113)                                    | <0.0001$^*$                                    |
|               | A2    | Placebo Control$^2$ | 17 (16, 29)                                   | 0/34 (0%)        |                                               |                                                 |                                               |
| B             | B1    | 1.0x BAT Product$^1$ | 26 (20, 29)                                   | 34/34 (100%)     | <0.0001$^*$                                    | 94 (94, 112)                                    | <0.0001$^*$                                    |
|               | B2    | Placebo Control$^2$ | 25 (19, 29)                                   | 1/34 (3%)        |                                               |                                                 |                                               |
| C             | C1    | 1.0x BAT Product$^1$ | 22 (12, 26)                                   | 33/34 (97%)      | <0.0001$^*$                                    | 114 (111, 141)                                  | <0.0001$^*$                                    |
|               | C2    | Placebo Control$^2$ | 22 (12, 26)                                   | 4/34 (12%)       |                                               |                                                 |                                               |
| D             | D1    | 1.0x BAT Product$^1$ | 24 (22, 37)                                   | 33/34 (97%)      | <0.0001$^*$                                    | 156 (141, 180)                                  | <0.0001$^*$                                    |
|               | D2    | Placebo Control$^2$ | 24 (22, 37)                                   | 5/34 (15%)       |                                               |                                                 |                                               |
| E             | E1    | 1.0x BAT Product$^1$ | 9 (7, 16)                                     | 34/34 (100%)     | <0.0001$^*$                                    | 29 (27, 30)                                    | <0.0001$^*$                                    |
|               | E2    | Placebo Control$^2$ | 8 (8, 10)                                     | 0/34 (0%)        |                                               |                                                 |                                               |
| F             | F1    | 1.0x BAT Product$^1$ | 15 (11, 20)                                   | 34/34 (100%)     | <0.0001$^*$                                    | 58 (45, 68)                                    | <0.0001$^*$                                    |
|               | F2    | Placebo Control$^2$ | 15 (10, 20)                                   | 4/34 (12%)       |                                               |                                                 |                                               |
| G             | G1    | 1.0x BAT Product$^1$ | 23 (15, 28)                                   | 34/34 (100%)     | <0.0001$^*$                                    | 168 (143, —)$^3$                                | <0.0001$^*$                                    |
|               | G2    | Placebo Control$^2$ | 22 (16, 29)                                   | 17/34 (50%)      |                                               |                                                 |                                               |

$^1$ Compared to proposed human clinical BAT product dose (mL/kg basis)

$^2$ Normal Equine Immune Globulin

$^3$ The upper bound of the 95 percent confidence interval could not be estimated due to the high incidence of censoring

$^4$ Treatment was triggered by four consecutive observations of moderate or severe signs of botulism intoxication;—Either animal death was not observed (groups A1, B1, E1, F1, and G1) or the Kaplan-Meier estimates could not be calculated due to censoring (groups C1 and D1)

$^*$ Comparison significant at the 0.05 level of significance.

https://doi.org/10.1371/journal.pone.0222670.t005
of mortality in the placebo group, a statistically significant improvement in survival of guinea pigs exposed to BoNT serotype G was achieved with BAT product treatment.

Two BAT product-treated animals died before the study end at 21 days; one intoxicated with BoNT serotype C (died on day 14) and one intoxicated with BoNT serotype D (died on day 8). In both deaths, the preceding clinical course was not consistent with BoNT intoxication progression. The cause of death could not be determined based on pathology. All placebo control animals (if surviving to the first weighing at either day 7 post-intoxication or upon exhibiting poor and deteriorating condition) lost weight before death. All but eight BAT product-treated animals gained weight throughout the post-intoxication period. The difference in weight changes between the treatment groups supports an overall clinical benefit with BAT product treatment (S1 Fig).

The median time to death could not be estimated for many of the treated groups since no mortality observed for BoNT serotypes A, B, E, F and G and only one death each was noted for serotypes C and D (Table 5). The treated groups had a significantly (p < 0.0001) longer time to death compared to placebo controls for all seven serotypes.

Treatment with BAT product substantially reduced the overall incidence of severe clinical signs compared to placebo (Table 6). Despite immediate intervention after the onset of clinical signs, almost all (~99%) BAT product-treated animals developed the clinical sign change in breathing rate/sound or pattern in addition to the right hind limb weakness (which was the treatment trigger in a majority of the cases) at rates consistent with the placebo group. However, there was a reduced incidence of other moderate clinical signs, including weak limbs, lacrimation and salivation with treatment groups compared to placebo groups. The overall incidence of weak limbs in treatment groups ranged between 8.8% (BoNT serotype D, 3/34) and 76.5% (BoNT serotype F, 26/34) compared to 100% (34/34) in each of the placebo groups. The incidence of lacrimation in placebo groups ranged between 8.8% (3/34, BoNT serotype A)
and 50% (17/34, BoNT serotype D) compared to a single BAT product-treated animal (BoNT serotype G). Salivation in treated animals was observed with exposure to BoNT serotype F (17.6%, 6/34) and BoNT serotype G (11.8%, 4/34), but was observed for all BoNT serotypes in placebo groups with incidence rates of between 8.8% (3/34) for BoNT serotype E and 91.2% (31/34) for BoNT serotype G. Incidence of severe signs of botulism was also higher in the placebo groups compared to treatment groups. For example, between 17.6% (BoNT serotypes C and D, both 6/34) and 97.1% (BoNT serotype F, 33/34) of placebo group animals exhibited forced abdominal respirations compared to only two BAT product-treated animals (one BoNT serotype C and one BoNT serotype F animal). Similarly, between 20.6% (BoNT serotype G, 7/34) and 100% (BoNT serotypes A and E, both 34/34) of placebo-treated animals progressed to total paralysis (severe sign requiring euthanasia) compared to 0% (0/34 for each serotype) of animals in the treatment groups. These results are indicative of the continued progression of the disease from mild to severe in placebo groups compared to the rapid arrest and subsequent reversal of the progress of illness among treated animals (Table 6).

Severe signs (forced abdominal respiration and total paralysis) of botulism were observed almost exclusively in the placebo control animals, although the exact incidence varied with each BoNT serotype. There was no incidence of forced abdominal respiration in the treated group for BoNT serotype A. A significantly lower incidence of forced abdominal respiration in most BoNT serotypes (serotypes A, B, D, E, F and G) and total paralysis in all seven BoNT serotypes was observed in treated groups compared to placebo groups (p < 0.05). Forced abdominal respiration was observed transiently (two consecutive half-hourly observations) for one animal intoxicated with BoNT serotype F and treated with BAT product. A second animal intoxicated with BoNT serotype C and treated with BAT product was found dead approximately three hours after first exhibiting forced abdominal respiration. Clinical progression was comparable between treatment and placebo groups but diverged approximately 21–58 hours post-treatment depending on the BoNT serotype (Fig 1). In general, the clinical severity scores demonstrate that for a period following intoxication and treatment, the clinical progression was comparable between BAT product and placebo groups; however, later, the clinical scores diverged. After this divergence the clinical severity score for BAT product-treated animals generally decreased as animals began to recover. In contrast, the clinical severity score for placebo-treated animals for most BoNT serotypes dramatically increased due to the onset of severe clinical signs or death. The clinical severity score continued to rise for placebo control animals until the end of the study or until all were dead or euthanized (Fig 1).

**Discussion**

BAT product is an equine-derived heptavalent antitoxin licensed under the Animal Rule (21 CFR 601.90–95) for treatment of symptomatic botulism following documented or suspected exposure to BoNT serotypes A, B, C, D, E, F or G in adult and pediatric patients. The demonstrated efficacy of BAT product in rhesus macaques [25] along with the therapeutic effectiveness of BAT product against all seven BoNT serotypes in guinea pigs exhibiting clinical signs consistent with botulism provided the evidence of effectiveness in support of licensure under the Animal Rule in the US. This report for the first time demonstrates the therapeutic efficacy of a botulinum antitoxin against all seven BoNT serotypes in symptomatic guinea pigs.

Guinea pigs are susceptible to all seven BoNT serotypes [22,30,31]. Our detailed clinical course studies in guinea pigs confirmed the susceptibility to all seven serotypes [21]. While the primary disease of botulism (progressive paralysis resulting in death) is comparable between guinea pigs, rhesus macaques and humans, specific details such as the onset of clinical disease differ between the species [32].
The results of the studies described here demonstrate the effectiveness of BAT product against all seven BoNT serotypes when administered to systemically intoxicated guinea pigs after the onset of definitive clinical signs of botulism. Consistent with our previous studies in macaques [25], intervention with BAT product did not result in an immediate cessation of disease progression, likely due to a portion of the toxin having already entered neuronal cells where it is no longer accessible to the BAT product. The significant survival (nearly 100%) obtained in guinea pigs is due to the administration of BAT product as soon as possible following the onset of non-transient signs of intoxication in each animal. This finding is similar to previous reports of improved survival in humans with early treatment [33–36]. Although survival rates were significantly higher in BAT product-treated animals irrespective of BoNT serotype, the mortality rate in placebo controls was not universal. In particular, a significant

**Fig 1. Mean clinical severity scores including scores for dead animals over time (Hours) by BoNT serotype and treatment group.**
Guinea pigs were intoxicated with 1.5x GPIMLD$_{50}$ of BoNT serotypes A, B, C, D, E, F or G and subsequently treated with 1.0x BAT product (dashed red line) or placebo (solid blue line). Treatment was initiated after four consecutive observations of moderate or severe signs of botulinum intoxication. Animals were assigned a score of 1 (mild signs of intoxication), 2 (moderate signs of intoxication) or 3 (severe signs of intoxication) at each timepoint. A value of 20 was assigned for the time at which an animal succumbed or was euthanized, and for all subsequent time points to end of the study.

https://doi.org/10.1371/journal.pone.0222670.g001
proportion (50%) of placebo control animals intoxicated with BoNT serotype G survived to
the end of the study. The lower than expected mortality was not believed to be due to an error
in dosing as toxin dose formulation results confirmed the target dose (S3 Table). The lower
than expected mortality is likely due to an inaccurate estimate of the LD$_{50}$. This is critical as
the 95% confidence intervals for the estimates of one GPIMLD$_{50}$ for all seven BoNT serotypes
are significant given the nature of the dose-response where a small increase in toxin dose is
capable of changing survival rates from 0% to 100% [21] and is compounded by the relatively
broad acceptance criteria associated with the toxin potency estimation due to the in vivo assay
method used (S3 Table). Also, the actual dose delivered was 15% less than the target dose
based on dose formulation analysis of challenge material. To address this uncertainty, the sam-
ple size determinations were made assuming survival rates of up to 65% for placebo-treated
animals and not less than 95% for BAT product-treated animals.

Clinical severity scores are relevant for assessing the predictive efficacy of BAT product in
human patients because of their comparability to the clinical scenario. In addition to survival
benefit, the treatment also reduced the severity of the disease. Although intravenous adminis-
tration of BAT product resulted in an immediate distribution within the circulatory system,
the severity scores of treated animals were comparable to placebo controls until 2–3 days post-
intoxication. The severity score for placebo control animals in most serotypes dramatically
increased after that time resulting in death or euthanasia. In contrast, almost all treated ani-
mals (>98%) recovered completely by day 21. When observed as a cohesive whole, these data
demonstrate the therapeutic efficacy of BAT product when given after the onset of systemic
clinical disease.

These findings are consistent with the clinical experience, where administration of antitoxin
did not result in immediate cessation in the clinical progression but did minimize the subsequent
severity of the disease [35]. The duration of the recovery phase in human cases can range from
several days to many months depending on the severity of the disease, serotype involved and
time of treatment [10,34,37,38]. Depending on the severity, botulism intoxication can require
extended periods of hospitalization and intensive care, which may not be feasible in a mass intox-
ication scenario [39]. Reducing the duration of hospital stays and the need for intensive care sup-
port with antitoxin treatment provide an opportunity for existing health care systems to
continue to function in a mass exposure event scenario. While animal-derived anti-BoNT immu-
noglobulins can be immunogenic and may cause adverse events when administered to another
species [39], no adverse events were noted in the animal studies presented. Overall, BAT product
was well tolerated, consistent with the subsequently demonstrated favorable risk-benefit profile
in patients with confirmed or suspected botulism treated with BAT product [36,40].

The significant protection obtained using the heptavalent antitoxin may be due to the poly-
clonal nature of the product that can target many different regions of the toxin and provide
broader biological activity by interfering at various steps in the toxin pathway. Several mono-
clonal antibodies (mAbs) under development against BoNT toxin serotypes (A, B, E and F)
have shown efficacy in animal models mostly in the form of a cocktail consisting of two or
more mAbs to cover the breadth of response against each target toxin and counter naturally
occurring toxin subtypes. The potential modification of toxin for use as a bioweapon limits the
utility of mAbs as therapeutics [41–47]. Also, there are significant barriers to supply and cost
with a monoclonal antibody treatment. Therefore, in a mass exposure event scenario, without
knowing the exact serotype involved, a heptavalent product that can neutralize the entire spec-
trum to BoNT serotypes with a single dose is an effective countermeasure for bioterrorism
concerns. For emergency preparedness and response, the United States government, through
the Biomedical Advanced Research and Development Authority, has stockpiled BAT product
in the Strategic National Stockpile.
The mechanism of action of BAT product is by the clearance of toxin in circulation and inhibiting the binding of the toxin to the neuronal cell surface receptor [48,49]. Published reports suggest that there is a correlation between the toxin dose and potential therapeutic window, and that antitoxin treatment is ineffective in experimental animals exposed to relatively high doses of BoNT [7,50]. Based on the standard neutralization capacity of one unit of toxin [21], and the large excess of antitoxin administered (relative to toxin exposure dose), the failure to rescue animals intoxicated with 4x GPIMLD$_{50}$ of botulinum toxin in Study 1 can be attributed to the rapid progression of the disease due to the high intoxication dose of BoNT. This is evidenced by the overlap in times to onset of moderate and severe signs of botulism intoxication in the placebo groups intoxicated with BoNT serotypes A D and F. It is likely that neurons internalized lethal amounts of toxin before treatment. Thus, it was necessary to identify an intoxication dose that provided a wider window of opportunity for treatment, while still highly lethal to the control group. There was a clear relationship between clinical progression and the toxin dose in Study 2, with an adequate window of opportunity at lower but still highly lethal toxin challenge dose under experimental conditions. The data reported here show that a challenge dose of 1.5x GPIMLD$_{50}$ of botulinum toxin is both relevant and reasonable for the evaluation of therapeutics against botulism intoxication.

In conclusion, a single dose of BAT product administered to symptomatic guinea pigs following exposure to lethal quantities of BoNT (A, B, C, D, E, F or G) resulted in a statistically significant survival benefit compared to placebo control. Also, the progression of the clinical signs associated with botulism intoxication was arrested with BAT product treatment. The results of these pivotal efficacy studies against all seven BoNT serotypes in guinea pig along with the efficacy against BoNT serotypes A in rhesus macaques [25] provided the evidence of effectiveness of BAT product in support of licensure under the Animal Rule in the US. Currently, BAT product is the only FDA approved treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F or G in adult and pediatric patients.

Supporting information

S1 Fig. Observed percent body weight changes by serotype and treatment group on Day 7, 10, 14 and 21 post-intoxication. Guinea pigs were intoxicated with 1.5x GPIMLD$_{50}$ of botulinum toxin serotypes A, B, C, D, E, F or G and subsequently treated with 1.0x BAT product (hollow blue circles) or placebo (hollow red triangles). Treatment was initiated after four consecutive observations of moderate or severe signs of botulism intoxication with surviving animals being weighed at 7, 10, 14 and 21 days post-intoxication. Data points are for individual animals and show changes in weight as a percentage of baseline body weight. (TIF)

S1 Table. GPIMLD$_{50}$ and Potency Values of BoNT Serotypes A, B, C, D, E, F, G. (DOCX)

S2 Table. Fold Excess Toxin Neutralization Capacity Provided by BAT Product When Administered as One Scaled Human Dose to Guinea Pigs Intoxicated with 4xGPIMLD$_{50}$ of BoNT Serotypes A, B, C, D, E, F, G. (DOCX)

S3 Table. Summary of BoNT potency results per serotype and percent target between average and target potency values. (DOCX)
Author Contributions

Conceptualization: Shantha Kodihalli.

Data curation: Douglas Barker, Karen T. Gillum.

Formal analysis: Nancy A. Niemuth.

Investigation: Karen T. Gillum.

Methodology: Karen T. Gillum.

Supervision: Douglas Barker, Shantha Kodihalli.

Writing – original draft: Douglas Barker, Shantha Kodihalli.

Writing – review & editing: Douglas Barker, Shantha Kodihalli.

References

1. Arnon SS, Schechter R, InglEsby TV, Henderson DA, Bartlett JG, Ascher MS et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001; 285:1059–1070. https://doi.org/10.1001/jama.285.8.1059 PMID: 11209178

2. Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology pharmacology and toxicology. Pharmacological reviews 2017; 69:200–235. https://doi.org/10.1124/pr.116.012658 PMID: 28356439

3. Rusnak JM, Smith LA. Botulinum neurotoxin vaccines: Past history and recent developments. Hum Vaccin 2009; 5:794–805. https://doi.org/10.4161/hv.9420 PMID: 19684478

4. Simpson LL. Botulinum Toxin. In: Barrett ADT and Stanberry LR, editors. Vaccines for Biodefense and Emerging and Neglected Diseases. New York: Academic Press; 2009. pp. 891–917.

5. Centers for Disease Control and Prevention (CDC). Botulism Annual Summary, 2017. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2019.

6. Gangarosa EJ, Donadio JA, Armstrong RW, Meyer KF, Brachman PS, Dowell VR. Botulism in the United States 1899–1969. Am J Epidemiol 1971; 93:93–101. https://doi.org/10.1093/oxfordjournals.aje.a121239 PMID: 4925448

7. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 1998; 129:221–228. https://doi.org/10.7326/0003-4819-129-3-19980801-00011 PMID: 9696731

8. Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Medicine and Public Health Preparedness 2007; 1(2):122–134. https://doi.org/10.1097/DMP.0b013e318158c5fd PMID: 1838640

9. Demarchi J, Mourguès C, Oriol J, Prevot AR. [Existence of type D botulism in man]. Bull Acad Natl Med 1958; 142:580–582. PMID: 13560962

10. Koenig MG, Drutz DJ, Mushlin AJ, Schaffner W, Rogers DE. Type B botulism in man. Am J Med 1967; 42:208–219. https://doi.org/10.1016/0002-9343(67)90020-4 PMID: 6018532

11. Mann JM, Martin S, Hoffman R, Marrazzo J. Patient recovery from type A botulism: morbidity assessment following a large outbreak. Am J Public Health 1981; 71:266–269. https://doi.org/10.2105/ajph.71.3.266 PMID: 7468858

12. McCroskey LM, Hatheway CL, Woodruff BA, Greenberg JA, Jurgenson P. Type F botulism due to neurotoxigenic Clostridium baratii from an unknown source in an adult. J Clin Microbiol 1991; 29:2618–2620. PMID: 1774272

13. Oguma K, Yokota K, Hayashi S, Takeshi K, Kumaagai M, Itoh N et al. Infant botulism due to Clostridium botulinum type C toxin. Lancet 1990; 336:1449–1450. https://doi.org/10.1016/0140-6736(90)93157-k

14. Seals JE, Snyder JD, Edell TA, Hatheway CL, Johnson CJ, Swanson RC et al. Restaurant-associated type A botulism: transmission by potato salad. Am J Epidemiol 1981; 113:436–444. https://doi.org/10.1093/oxfordjournals.aje.a113111 PMID: 7010999

15. Botulism Sobel J. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2005; 41:1167–1173. https://doi.org/10.1086/444507

16. Sonnabend O, Sonnabend W, Heinzle R, Sigrist T, Dimhofer R, Krech U. Isolation of Clostridium botulinum type G and identification of type G botulinum toxin in humans: report of five sudden unexpected deaths. J Infect Dis 1981; 143:22–27. https://doi.org/10.1093/infdis/143.1.22 PMID: 7012244
17. Telzak EE, Bell EP, Kautter DA, Crowell L, Budnick LD, Morse DL et al. An international outbreak of type E botulism due to unviscerated fish. J Infect Dis 1990; 161:340–342. https://doi.org/10.1093/infdis/161.2.340 PMID: 2405071

18. Terranova W, Bremen JG, Locey RP, Speck S. Botulism type B: epidemiologic aspects of an extensive outbreak. Am J Epidemiol 1978; 108:150–156. https://doi.org/10.1093/oxfordjournals.aje.a112599 PMID: 707476

19. Townes JM, Cieslak PR, Hatheway CL, Solomon HM, Holloway JT, Baker MP et al. An outbreak of type A botulism associated with a commercial cheese sauce. Ann Intern Med 1996; 125:558–563. https://doi.org/10.7326/0003-4819-125-7-199610010-00004 PMID: 8815754

20. Weber JT, Hibbs RG Jr, Danwisch A, Mishu B, Corwin AL, Rakha M et al. A massive outbreak of type E botulism associated with traditional salted fish in Cairo. J Infect Dis 1993; 167:451–454. https://doi.org/10.1093/infdis/167.2.451 PMID: 8421179

21. Emanuel A, Qiu H, Barker D, Takla T, Gillum K, Neimuth N et al. Efficacy of equine botulism antitoxin in botulism poisoning in a guinea pig model. PLoS One 2018; 14(1):e0209019. https://doi.org/10.1371/journal.pone.0209019 PMID: 30633746

22. Cardella MA. Botulinum Toxoids. In: Lewis KH editor. Botulism: Proceedings of a Symposium. Washington, DC: Government Printing Office; PHS Publication; 1964. pp. 113–130.

23. Gelzleichter TR, Myers MA, Menton RG, Niemuth NA, Matthews MC, Langford M.J. Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J Appl Toxicol 1999; 19 Suppl 1:S35–38.

24. Metzger JF, Lewis GE Jr. Human-derived immune globulins for the treatment of botulism. Rev Infect Dis 1979; 1:689–692. https://doi.org/10.1093/clinids/1.4.689 PMID: 399376

25. Kodihalli S, Emanuel A, Takla T, Hua Y, Hobbs C, LeClaire R et al. Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques. PLoS One 2017; 12:e0186892. https://doi.org/10.1371/journal.pone.0186892 PMID: 29166654

26. National Research Council (US) Institute for Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academies Press (US); 1996.

27. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004; 44:167–193. https://doi.org/10.1146/annurev.pharmtox.44.101802.121554 PMID: 14744243

28. FDA. Guidance for Industry Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER); 2005. Available from: https://www.fda.gov/media/72309/download. Cited 20 June 2019.

29. FDA. Product Development Under the Animal Rule Guidance for Industry. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER); 2015. Available from: https://www.fda.gov/media/88625/download. Cited 20 June 2019.

30. Ciccarelli AS, Whaley DN, McCroskey LM, Gimenez DF, Dowell VR Jr, Hatheway CL. Cultural and physiological characteristics of Clostridium botulinum type G and the susceptibility of certain animals to its toxin. Appl Environ Microbiol 1977; 34:843–848. PMID: 74236

31. Harvey SM, Sturgeon J, Dassey DE. Botulism due to Clostridium baratii type F toxin. J Clin Microbiol 2002; 40:2260–2262. https://doi.org/10.1128/JCM.40.6.2260-2262.2002 PMID: 12037104

32. Middlebrook JL, Franz DR. Botulimum Toxins. In: Sidel FR, Takafuji ET and Franz DR, editors. Medical Aspects of Clinical and Biological Warfare. Washington, D.C.: United States Government Printing; 1997. pp. 643–654.

33. Kongsaengdao S, Samantarapanyka K, Rusmeechan S, Wongsa A, Pothirat C, Permpikul C et al. An outbreak of botulism in Thailand: clinical manifestations and management of severe respiratory failure. Clin Infect Dis 2006; 43:1247–1256. https://doi.org/10.1086/508176 PMID: 17051488

34. McCarty CL, Angelo K, Beer KD, Cibulska-White K, Quinn K, de Fijter S et al. Large Outbreak of Botulism Associated with a Church Potluck Meal—Ohio 2015. MMWR. Morb Mortal Wkly Rep 2015; 64:802–803.

35. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984; 76:794–798. https://doi.org/10.1016/0002-9343(84)90988-4 PMID: 6720725

36. Richardson JS, Parrera GS, Astacio H, Sahota H, Anderson DM, Hall C et al. Safety and clinical outcomes of an equine-derived heptavalent botulinum antitoxin treatment for confirmed or suspected botulism in the United States. Clin Infect Dis 2019; pii:ciz515. https://doi.org/10.1093/cid/ciz515 PMID: 31209461
37. Ball AP, Hopkinson RB, Farrell ID, Hutchison JG, Paul R, Watson RD et al. Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak. Q J Med 1979; 48:473–491. PMID: 575566
38. Colebatch JG, Wolff AH, Gilbert RJ, Mathias CJ, Smith SE, Hirsch N et al. Slow recovery from severe foodborne botulism. Lancet 1989; 2:1216–1217. https://doi.org/10.1016/0140-6736(89)91822-9
39. Kris E, Burnett JC, Kane CD, Bavari S. Recent advances in botulinum neurotoxin inhibitor development. Curr Top Med Chem 2014; 14:2044–2061. https://doi.org/10.2174/1568026614012090350 PMID: 25335887
40. Yu PA, Lin NH, Mahon BE, Sobel J, Yu Y, Mody RK et al. Safety and improved clinical outcomes in patients treated with new equine-derived heptavalent botulinum antitoxin. Clin Infect Dis. 2018; 66 (Suppl 1):S57–S64. https://doi.org/10.1093/cid/cix816 PMID: 29293928
41. Cheng W, Joshu SB, He F, Brems DN, He B, Kerwin BA et al. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements. J Pharm Sci 2012; 101:1701–1720. https://doi.org/10.1002/jps.23076 PMID: 22323186
42. Derman Y, Selby K, Miethe S, Frenzel A, Liu Y, Rasetti-Escargueil C et al. Neutralization of botulinum neurotoxin type E by a humanized antibody. Toxins 2016; 8(9):257. https://doi.org/10.3390/toxins8090257 PMID: 27626446
43. Fan Y, Garcia-Rodriguez C, Lou J, Wen W, Conrad F, Zhai W et al. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. PLoS One 2017; 12: e0174187. https://doi.org/10.1371/journal.pone.0174187 PMID: 28323873
44. Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH et al. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype E subtypes. Toxins 2018; 10 (3):105. https://doi.org/10.3390/toxins10030105 PMID: 29494481
45. Adekar SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DM, Root MJ et al. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One 2008; 3:e3023. https://doi.org/10.1371/journal.pone.0003023 PMID: 18714390
46. Li M, Lee D, Obi CR, Freeberg JK, Farr-Jones S, Tomic MT. An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E. PLoS One 2018; 13: e0197011. https://doi.org/10.1371/journal.pone.0197011 PMID: 29746518
47. Takahashi H, Kitagawa Y, Maeda-Satoh M, Hasegawa H, Sawa H, Sata T. Monoclonal antibody and siRNAs for topoisomerase I suppress telomerase activity. Hybridoma (2005) 2009; 28:63–65. https://doi.org/10.1089/hyb.2008.0066 PMID: 19132895
48. Atassi MZ, Oshima M. Structure activity and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol 1999; 19:219–260. PMID: 10422600
49. Cheng LW, Stanker LH, Henderson TD 2nd, Lou J, Marks JD. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 2009; 77:4305–4313. https://doi.org/10.1128/IAI.00405-09 PMID: 19651864
50. Ravichandran E, Gong Y, Al Saleem FH, Ancharski DM, Joshi SG, Simpson LL. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 2006; 318: 1343–1351 https://doi.org/10.1124/jpet.106.104661 PMID: 16782822